Lyme disease vaccine - sanofi pasteur

Drug Profile

Lyme disease vaccine - sanofi pasteur

Alternative Names: ImuLyme

Latest Information Update: 29 Jan 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Symbicom
  • Developer sanofi pasteur
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Lyme disease

Most Recent Events

  • 19 Jan 2005 Aventis Pasteur is now called sanofi pasteur
  • 30 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 10 Jul 2000 An analysis of immune sera from volunteers in the phase III trial has been added to the Bacterial Infections therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top